Rodin taps Adam Rosenberg for top post

Rodin CEO Adam Rosenberg

Cambridge, MA-based Rodin Therapeutics has recruited biotech vet Adam Rosenberg as its new CEO. Rosenberg plans to stay on as head of Teleos Therapeutics, which is in the business of doing drug discovery work for CNS diseases, until a replacement is found. Rodin is working on an HDAC2 inhibitor for Alzheimer's and other cognitive diseases. Release

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.